Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 33616314

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2021 Apr 8
First author
Motzer R

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    N Engl J Med. 2021 Apr 8;384(14):1360-1361. doi: 10.1056/NEJMe2101777.
    note
    Source null
    related pmid
    33616313
    relationship
    Comment in
  2. citation
    Nat Med. 2021 Apr;27(4):586-588. doi: 10.1038/s41591-021-01320-x.
    note
    Source null
    related pmid
    33820997
    relationship
    Comment in
  3. citation
    N Engl J Med. 2021 Jul 15;385(3):287. doi: 10.1056/NEJMc2107518.
    note
    Source null
    related pmid
    34260845
    relationship
    Comment in
  4. citation
    J Urol. 2021 Dec;206(6):1517-1519. doi: 10.1097/JU.0000000000002213.
    note
    Source null
    related pmid
    34494452
    relationship
    Comment in
  5. citation
    Chemotherapy. 2021;66(5-6):196-198. doi: 10.1159/000518500.
    note
    Source null
    related pmid
    34818222
    relationship
    Comment in

Authors and identifiers

  1. name
    Motzer R
    type
    Author
  2. name
    Alekseev B
    type
    Author
  3. name
    Rha SY
    type
    Author
  4. name
    Porta C
    type
    Author
  5. name
    Eto M
    type
    Author
  6. name
    Powles T
    type
    Author
  7. name
    Grünwald V
    type
    Author
  8. name
    Hutson TE
    type
    Author
  9. name
    Kopyltsov E
    type
    Author
  10. name
    Méndez-Vidal MJ
    type
    Author
  11. name
    Kozlov V
    type
    Author
  12. name
    Alyasova A
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Motzer R
    type
    Author
  2. name
    Alekseev B
    type
    Author
  3. name
    Rha SY
    type
    Author
  4. name
    Porta C
    type
    Author
  5. name
    Eto M
    type
    Author
  6. name
    Powles T
    type
    Author
  7. name
    Grünwald V
    type
    Author
  8. name
    Hutson TE
    type
    Author
  9. name
    Kopyltsov E
    type
    Author
  10. name
    Méndez-Vidal MJ
    type
    Author
  11. name
    Kozlov V
    type
    Author
  12. name
    Alyasova A
    type
    Author
bibliography ids
  1. nci-bib-24e4f0642842856e637f6eba
book metadata
content sha256
f48e23f3ff074cfe96c055c0af062409ece4d2d5d8c1d3a2dd67ba8627c07734
document type
citation
dois
  1. 10.1056/NEJMoa2035716
electronic publication date
display
2021 Feb 13
precision
day
year
2021
evidence scope
bibliographic_metadata_only
id
pubmed:33616314
immutable id
pubmed:33616314@f48e23f3ff074cfe96c055c0af062409ece4d2d5d8c1d3a2dd67ba8627c07734
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
14
name
The New England journal of medicine
nlm unique id
0255562
pages
1289-1300
volume
384
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    N Engl J Med. 2021 Apr 8;384(14):1360-1361. doi: 10.1056/NEJMe2101777.
    note
    Source null
    related pmid
    33616313
    relationship
    Comment in
  2. citation
    Nat Med. 2021 Apr;27(4):586-588. doi: 10.1038/s41591-021-01320-x.
    note
    Source null
    related pmid
    33820997
    relationship
    Comment in
  3. citation
    N Engl J Med. 2021 Jul 15;385(3):287. doi: 10.1056/NEJMc2107518.
    note
    Source null
    related pmid
    34260845
    relationship
    Comment in
  4. citation
    J Urol. 2021 Dec;206(6):1517-1519. doi: 10.1097/JU.0000000000002213.
    note
    Source null
    related pmid
    34494452
    relationship
    Comment in
  5. citation
    Chemotherapy. 2021;66(5-6):196-198. doi: 10.1159/000518500.
    note
    Source null
    related pmid
    34818222
    relationship
    Comment in
outcomes validated
false
pmid
33616314
provenance
batch id
79f1021053e858d13ff3
provider
NCBI PubMed ESummary
record sha256
a9e748939b8fb1dfbb3ba6aedf4ed96ea13c88fd999d38f3267ce3b8c6893ad5
response sha256
671d3d2962f73c698a1cb338d73222e2cc6cfdf61569f91b42612d5b59822e05
retrieved at
2026-09-09T23:47:59.098265+00:00
publication date
display
2021 Apr 8
precision
day
year
2021
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, N.I.H., Extramural
  7. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/33616314/
title
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.

Preserved source evidence · Not medical advice